Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses

Inclusion Criteria:

• Adults 18 to 60 years of age.
• Body mass index (BMI) between 25 and 35 kilograms per square meter (kg/m^2), inclusive.
• Stable body weight, with less than 5 kilograms (kg) (11 pounds) of weight change in the past 3 months.
• No significant changes in diet or eating habits in the past 3 months.
• Generally healthy. People with certain well-controlled medical conditions, such as sleep apnea, high blood pressure, high cholesterol, or underactive thyroid, may qualify if their treatment has been stable for at least 3 months and is approved by the study doctor.
• Willing to follow the study's birth control requirements, if applicable, during the study and for the study-defined period after the last dose of study drug.
• Able and willing to provide informed consent before participating in study procedures.

Exclusion Criteria:

• History of diabetes or current diabetes, except diabetes during pregnancy, or blood sugar levels that meet the study's definition of diabetes.
• Certain hormonal conditions that can cause weight gain, such as Cushing's syndrome.
• History of pancreatitis (inflammation of the pancreas) or certain abnormal pancreatic blood test results.
• History of cancer within the past 5 years, except certain early-stage cancers or nonmelanoma skin cancers.
• Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2).
• Uncontrolled thyroid disease or certain abnormal thyroid blood test results.
• Significant stomach or intestinal conditions, including delayed stomach emptying, ulcers, or inflammatory bowel disease, or a history of certain digestive system surgeries.
• Weight-loss surgery within the past 6 months.
• Significant heart disease, abnormal heart rhythms, or blood pressure or heart rate outside the study's allowed limits.
• Significant kidney or liver problems, or certain abnormal kidney or liver blood test results.
• Positive tests for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, with certain exceptions for past hepatitis B vaccination or infection.
• History of certain serious or unstable mental health conditions, self-injury within the past 5 years, or any previous suicide attempt.
• History of ischemic optic neuropathy, a condition involving damage to the optic nerve caused by reduced blood flow.
• Allergy or intolerance to maridebart cafraglutide (AMG 133), similar medications, or their ingredients.
• Use of certain medications, including weight-loss or diabetes medications that act on glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP), within the restricted time periods before the study.
• Use of certain herbal products, vitamins, or supplements within 30 days before enrollment, unless approved by the study doctor.
• Recent participation in another investigational drug study or previous participation in a study of maridebart cafraglutide.
• History of alcohol or drug abuse, recent illegal drug use, or positive alcohol or drug screening results not explained by permitted prescription medications.
• Pregnant, breastfeeding, or planning to breastfeed during the study or within the study-defined period after the last dose of study drug.
• Recent blood, plasma, or platelet donation within the study's restricted time periods.
• Recent strenuous exercise or unwillingness to follow study restrictions on physical activity, alcohol, recreational drugs, diet, or other activities.
• Difficulty providing blood samples because of poor vein access.
• Any other medical condition, abnormal test result, or circumstance that the study doctor believes could make participation unsafe or interfere with study procedures.